Mitoxantrone treatment of multiple sclerosis: safety considerations.
about
Natalizumab: A new treatment for relapsing remitting multiple sclerosisEvaluating the Role of Corticosteroid Pulse Therapy in Patients With Secondary Progressive Multiple Sclerosis Receiving Mitoxantrone: A Double Blind Randomized Controlled Clinical Trial.The symptomatic management of multiple sclerosis.Cardiotoxicity and other adverse events associated with mitoxantrone treatment for MS.Toxicities of immunosuppressive treatment of autoimmune neurologic diseases.Early mitoxantrone-induced cardiotoxicity in secondary progressive multiple sclerosis.New insights into neuromyelitis opticaThe cardiac effects of mitoxantrone: do the benefits in multiple sclerosis outweigh the risks?Multiple sclerosis disease-modifying therapies: adverse effect surveillance and management.Fetal risks related to the treatment of multiple sclerosis during pregnancy and breastfeeding.Usefulness of myocardial performance index in multiple sclerosis mitoxantrone-induced cardiotoxicityFemale-specific issues in multiple sclerosis.Role of intraspinal steroid application in patients with multiple sclerosis.Mitoxantrone: benefits and risks in multiple sclerosis patients.Disease-modifying treatments for progressive multiple sclerosis.Efficacy and safety of mitoxantrone use in primary and secondary progressive multiple sclerosis - study site experience based on the therapy of 104 patients.Comparative study of mitoxantrone efficacy profile in patients with relapsing-remitting and secondary progressive multiple sclerosis.Mitoxantrone treatment in multiple sclerosis induces TH2-type cytokines.Suppression of mitoxantrone cardiotoxicity in multiple sclerosis patients by dexrazoxane.Chronic myeloid leukemia associated with mitoxantrone treatment in a patient with MS.Adoptive transfer of T(reg) depleted autologous T cells in advanced renal cell carcinoma.High-dose cyclophosphamide in the treatment of multiple sclerosis.Adipose-derived mesenchymal stem cells (AdMSC) for the treatment of secondary-progressive multiple sclerosis: A triple blinded, placebo controlled, randomized phase I/II safety and feasibility study.Early mitoxantrone-induced cardiotoxicity in secondary progressive multiple sclerosis
P2860
Q24683014-2F95B182-B110-43F9-BDB3-D268EE50D070Q31023281-A5414AEE-6DD9-4ABF-8288-6CA83315FC51Q33670955-6AFBACF2-C725-4E91-A8DC-78915D9BD47FQ33899881-5E6241E0-8DC5-4D39-BD30-532BB9F490ECQ34257903-7E52D261-8C9F-4671-BBAE-BE6D6B4160FAQ34535269-2C4A4F4B-2BD1-4FCC-BA23-CBFC4897A7C0Q35539641-0754D2AB-6599-457D-916F-0C692C07683FQ36407273-0FD1A425-595B-4A71-93A8-8787D88E32C4Q36419566-D3633AFA-E31E-47A1-8D74-12BFC7A87756Q36688987-9D01A49F-F695-47D4-8B84-EC8D810E9B87Q36982852-F7BF0383-1647-4B57-B29C-F082C7D8F0DCQ37174067-3675F180-6515-4DF8-AD49-69A05874B0CEQ37600855-E5620CBB-D499-4E93-BCE4-FD58280938C2Q37625917-8CDC8999-D9CE-4B5E-B75F-8150083BA136Q38142030-918B9549-F822-4CB5-91F1-657B8C560F85Q40423250-413347F2-5063-43FE-BBDD-7B78461536F5Q42920232-6476117B-3F97-44D1-92B0-957AB0A0BC33Q43238677-FDF16FD0-2845-4D48-A49A-FB7FD71D4650Q46865786-6E8B40B1-3F35-45D4-87F4-2BF818B84ED0Q46912031-EE839740-500A-46DB-9F5C-D448BBC89A5FQ46979111-9EE2CDA8-20C6-45FE-A736-585D8CA589FAQ48726092-04F686D7-2D9D-4734-9A99-A64EE6DE17E7Q54210026-113DC248-876F-4479-B0D2-556DE6BB6978Q56986554-571230BF-E149-43F6-847D-BD0390AEB146
P2860
Mitoxantrone treatment of multiple sclerosis: safety considerations.
description
2004 nî lūn-bûn
@nan
2004年の論文
@ja
2004年論文
@yue
2004年論文
@zh-hant
2004年論文
@zh-hk
2004年論文
@zh-mo
2004年論文
@zh-tw
2004年论文
@wuu
2004年论文
@zh
2004年论文
@zh-cn
name
Mitoxantrone treatment of multiple sclerosis: safety considerations.
@ast
Mitoxantrone treatment of multiple sclerosis: safety considerations.
@en
type
label
Mitoxantrone treatment of multiple sclerosis: safety considerations.
@ast
Mitoxantrone treatment of multiple sclerosis: safety considerations.
@en
prefLabel
Mitoxantrone treatment of multiple sclerosis: safety considerations.
@ast
Mitoxantrone treatment of multiple sclerosis: safety considerations.
@en
P1433
P1476
Mitoxantrone treatment of multiple sclerosis: safety considerations.
@en
P2093
Bruce A Cohen
Daniel D Mikol
P304
P356
10.1212/WNL.63.12_SUPPL_6.S28
P407
P433
12 Suppl 6
P577
2004-12-01T00:00:00Z